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Male osteoporosis continues to be under-recognized and undertreated in men. An understanding of which
factors cue clinicians about osteoporosis risk in men, and which do not, is needed to identify areas for im-
provement. This study sought to measure the association of a provider's recognition of osteoporosis with pa-
tient information constructs that are available at the time of each encounter. Using clinical and administrative
data from the Veterans Health Administration system, we used a stepwise procedure to construct prognostic
models for a combined outcome of osteoporosis diagnosis, treatment, or a bone mineral density (BMD) test
order using time-varying covariates and Cox regression. We ran separate models for patients with at least
one primary care visit and patients with only secondary care visits in the pre-index period. Some of the stron-
gest predictors of clinical osteoporosis identification were history of gonadotropin-releasing hormone
(GnRH) agonist exposure, fragility fractures, and diagnosis of rheumatoid arthritis. Other characteristics as-
sociated with a higher likelihood of having osteoporosis risk recognized were underweight or normal body
mass index, cancer, fall history, and thyroid disease. Medication exposures associated with osteoporosis
risk recognition included opioids, glucocorticoids, and antidepressants. Several known clinical risk factors
for fracture were not correlated with osteoporosis risk including smoking and alcohol abuse. Results suggest
that clinicians are relying on some, but not all, clinical risk factors when assessing osteoporosis risk.
© 2011 Elsevier Inc. All rights reserved.
Introduction
As the median age of the US population increases, hip fracture
rates are expected to double by the year 2040 [1]. The direct medical
cost of osteoporotic fractures in the United States (US) was $17 billion
in 2005 [2]. Because of the substantial clinical and economic burden
associated with osteoporotic fractures, the National Osteoporosis
Foundation (NOF) and International Society for Clinical Densitometry
(ISCD) have recommended bone mineral density (BMD) testing for
men over the age of 70 [3,4].
Reports continue to show that osteoporosis is evenmore drastically
under-diagnosed and under-treated in men than in women [5–9]. In a
cohort of managed care patients, only 7% of men with a prior fragility
fracture received osteoporosis-specific medication [7], compared to
20–24% of women [6,8]. One hospital-based study showed that the
rate of post-fracture treatment in men was half that of women with
the same risk factors [9]. In addition, when men do break a bone, they
experience worse outcomes. Hip fractures are twice as deadly for men
compared to women [10], and physical functioning also deteriorates
more for men following hip fractures [11].
The reasons for this under-treatment and its consequences are not
well understood. Several published studies have evaluated the osteo-
porosis clinical decision-making processes – including predictors of
treatment, diagnosis, and BMD testing – in both sexes [12–15], and
one study has looked exclusively at males [7]. Unfortunately, taken
together, these studies are limited in their applicability to US men.
For instance, one study evaluated a non-US population, and so does
not reflect patterns of care in the US [12]. Most other studies failed
to evaluate predictors separately for men and women [13–15]. This
is essential because, as Vanasse and colleagues showed in a cohort
of Quebecois, predictors of treatment and BMD testing differ substan-
tially between men and women [12]. Some studies were based on pa-
tient surveys rather than data from clinical encounters [13,15], which
would exclude data observable to clinicians as potential cues. One of
the studies focused only on treatment decisions post-fracture and so
failed to provide useful information about interventions intended to
prevent the first fracture [7]. Finally, none of the prior analyses mod-
eled the predictors so as to allow patient characteristics to vary over
time. This is important because characteristics that develop in close
temporal proximity to a treatment or screening decision are more
likely to be cues for that decision.
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Our goal in this study was to improve upon thework done by others
[7,12–15] and identify characteristics that cue clinicians to identify oste-
oporosis or osteoporosis risk amongmen. To that end, we modeled po-
tential predictors of diagnosis, treatment, or BMD testing using a male
US veteran population.We used time-varying Cox proportional hazards
modeling with time-varying covariates to enhance discrimination of
factors that were temporally associated with clinical identification, as
well as information constructs that were observable to clinicians in
the patient care record at the time of each encounter. Finally, because
recognition of osteoporosis may vary by the type of provider, we strat-
ified our analysis based on wether patients were seen for primary care
or specialty care needs.
Methods
Study design and patients
We used a historical cohort design to evaluate the association be-
tween observable clinical characteristics and outcomes related to
clinically identified osteoporosis or fracture risk. Our primary end-
point was a composite outcome we termed “clinical identification of
osteoporosis or fracture risk,” defined as the first documentation of
an event that indicates the clinician was aware of osteoporosis risk.
We identified male veterans who received care in the Veterans
Health Administration (VHA) system in the Rocky Mountain region of
the US (Veterans Integrated Service Network [VISN] 19) in 2005–2006
andwhowere≥70 years by January 1, 2005. This age cutoff was chosen
due to the NOF's and ISCD's recommendation of BMD testing for all men
age 70.We excluded patients without a prior encounter in the VHA sys-
tem at least 395 days before their index encounter (the first encounter
in 2005–2006) in order to ensure an adequate period of observation for
assessing baseline characteristics. We also excluded patients who had
the composite outcome of interest as of the index date (an osteoporosis
diagnosis, an osteoporosis treatment, or a BMD test order). Patients
with missing body mass index (BMI) information were excluded in an
iterative manner. We originally intended to include these patients, but
upon discovering that BMIwas an important variable in predicting clin-
ical identification of osteoporosis or fracture risk, we ultimately decided
to exclude them. Administrative data from 2002 through 2007 were
obtained including diagnoses and procedures from the VHA National
Medical SAS datasets and vital signs and pharmacy data from the VHA
local data warehouse. Patients were censored at the first occurrence of
an outcome or on December 31, 2007, whichever occurred first. Finally,
patients were considered primary care patients if they had at least one
primary care visit in the VHA prior to the index date. Patients without a
primary care visit were considered specialty care patients.
Outcome
The outcome of interest in this study was the first occurrence after
the index date of an event suggesting clinical identification of osteoporo-
sis or osteoporosis risk. This was defined as either (1) a diagnosis of os-
teoporosis, indicated by diagnosis codes 733**; (2) a prescription order
for calcitonin, parathyroid hormone, or an osteoporosis bisphosphonate
(i.e., alendronate, ibandronate, or risedronate; zoledronic acid was not
yet marketed during the study period) dispensed from the outpatient
pharmacy; or (3) an order for a BMD test, indicated by current procedur-
al terminology (CPT) codes for dual-energy X-ray absorptiometry, quan-
titative computed tomography, qualitative ultrasound, single and dual
photon absorptiometry, digital X-ray radiogrammetry, and single energy
X-ray absorptiometry.
Independent variables
Predictors of osteoporosis recognition that we considered includ-
ed variables with a known or theoretical association with bone health
or fall risk (e.g., age, BMI, race), comorbid conditions, drug exposures,
and the number of inpatient and outpatient visits in the year prior to
the index date (a surrogate marker for system familiarity with the pa-
tient). Each predictor variable was characterized at baseline, as far
back as January 1, 2002. Each predictor variable was also allowed to
change each quarter during follow-up period, with patients contrib-
uting person-time to different levels for each covariate as the pa-
tients' clinical characteristics changed over time.
Statistical analysis
Descriptive statistics were used to characterize the baseline demo-
graphic and clinical characteristics of our cohort. We then performed a
series of univariate Cox proportional hazards regressions with time-
varying covariates to determine if predictors were significantly associat-
ed with clinical identification of osteoporosis. Risk factors that were sig-
nificant in univariate analyses at an a priori alpha level of 0.2 were
considered candidate risk factors. We then performed a multivariable
stepwise selection procedure, inwhich candidate risk factors were intro-
duced one at a time and those with p-values>0.10 were excluded. A
stepwise selection procedure was used because of the predictive nature
of our research question. Because the candidate variables in our model
are pre-specified, i.e. identified based on association with bone health
or fall risk from previous studies, a multiplicity adjustment is not war-
ranted here [16]. All statistical tests were performed using SAS v. 9.2.
Results
Patients
Of the 48,183 males who met the inclusion criteria, we excluded
2452 (2.3%) who had the outcome of interest on or before baseline
and 11,449 (23.2%) with missing or invalid BMI data. This resulted in
a cohort of 34,282 patients, 9037 of whom were primary care patients
and 25,245 of whom were specialty care patients. Descriptive charac-
teristics of the patients at baseline are summarized in Table 1. The two
groups of patients were similar in terms of race (91.2% of primary care
patients and 91.8% of specialty care patients werewhite)while primary
care patients (40.8% age 80 or older) were older than specialty care pa-
tients (31.4% age 80 or older). Themost common diseases as of baseline
for both groups of patients were hypertension (85.4% for primary care
patients; 79.1% for specialty care patients), diabetes (54.3% for primary
care patients; 46.7% for specialty care patients), and cancer (32.8% for
primary care patients; 20.3% for specialty care patients). Statins were
the most common medication for which previous exposure was cap-
tured for both primary care (56.8%) and secondary care patients
(55.8%). Nearly half of the primary care patients had been exposed to
opioids at baseline (47.8%) and roughly one-third had a history of expo-
sure to thiazide diuretics (34.6%) and H-2 receptor antagonists (30.1%)
at baseline. Similarly, exposure to thiazide diuretics (29.4%) and H-2 re-
ceptor antagonists (19.1%) was common among specialty care patients.
Both the primary and specialty care patients had an average follow-
up time of 2.8 years. During this follow-up time 467 (5.2%) of the 9037
primary care patients and 782 (3.1%) of the 25,245 specialty care pa-
tients had the composite endpoint. This corresponds to an incidence
of 18.3 events and 11.3 events per 1000 person-years, respectively.
Among those who had the outcome, the average time to clinical identi-
fication of osteoporosis or fracture risk was 1.4 years for both groups of
patients.
Clinical identification of osteoporosis or osteoporosis risk in primary care
patients
The predictive model results are summarized in Table 2. In the
multivariable model for primary care patients, neither race nor age
was a significant predictor of clinical identification of osteoporosis.
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The strongest predictors of clinical identification for primary care pa-
tients were documented histories of gonadotropin releasing hormone
(GnRH) exposure (hazard ratio [HR] 2.8, pb .0001), fragility fractures
(HR 2.4, pb .0001) and diagnosis of rheumatoid arthritis (HR 2.0,
p=0.001). Clinicians were also more likely to identify osteoporosis
or fracture risk in underweight or normal weight patients compared
to patients who were overweight or obese and patients with histories
of cancer, deep vein thrombosis, falls, malnutrition disorder, and pa-
tients with exposure to glucocorticoids, loop diuretics, and opioids.
Clinicians were less likely to identify osteoporosis or fracture risk in
patients with stroke. Interestingly, some clinical risk factors for frac-
ture that were not associated with the composite outcome were
smoking and alcohol abuse. The number of visits in the year prior to
the index date (our surrogate for “system familiarity”) also failed to
predict the outcome with any accuracy.
Clinical identification of osteoporosis or osteoporosis risk in specialty
care patients
In the multivariable model for specialty care models, BMI and sys-
tem familiarity were significant predictors of clinical identification of
osteoporosis but age and race were not. Similar to primary care pa-
tients, documented history of GnRH exposure (HR 4.1, pb .0001), fra-
gility fractures (HR 3.0, pb .0001), and rheumatoid arthritis (HR 2.8,
Table 1
Frequency of risk factors of clinical identification of osteoporosis or fracture riska at baseline and number of patients identified with each risk factor.
Primary Care Visit (N=9037) Specialty Care Visits Only (N=25,245)
Frequency at Baseline Number with Events Frequency at Baseline Number with Events
Characteristic N % N % N % N %
Age
70–74 (ref) 2133 23.6 94 4.4 9775 38.7 286 2.9
75–79 vs. 70–74 3218 35.6 162 5.0 7540 29.9 232 3.1
≥80 vs. 70–74 3686 40.8 211 5.7 7930 31.4 264 3.3
BMI
Normal/underweight vs. overweight/obese 2686 29.7 167 6.2 6699 26.5 295 4.4
Visit densityb
b 10 (ref) 672 7.4 26 3.9 7786 30.8 170 2.2
10–19 vs. b 10 1379 15.3 46 3.3 7744 30.7 199 2.6
20–29 vs. b 10 2753 30.5 123 4.5 6244 24.7 233 3.7
30–39 vs. b 10 4233 46.8 272 6.4 3471 13.7 180 5.2
White vs. non-whitec 5555 91.2 310 5.6 9050 91.8 332 3.7
Pre-existing conditions or exposuresd
Alcohol abuse-related disorder 428 4.7 18 4.2 551 2.2 24 4.4
Blindness 1235 13.7 60 4.9 1733 6.9 72 4.2
Cancer 2960 32.8 210 7.1 5123 20.3 245 4.8
Deep vein thrombosis 331 3.7 27 8.2 438 1.7 18 4.1
Depression 1788 19.8 103 5.8 2899 11.5 132 4.6
Diabetes 4903 54.3 268 5.5 11,793 46.7 378 3.2
Falls 625 6.9 44 7.0 387 1.5 15 3.9
Fragility fracture 180 2.0 13 7.2 106 0.4 11 10.4
Heart failure 1872 20.7 96 5.1 2133 8.4 80 3.8
Hypertension 7715 85.4 394 5.1 19,964 79.1 608 3.0
Malnutrition disorder 860 9.5 58 6.7 682 2.7 41 6.0
Myocardial infarction 1086 12.0 56 5.2 1633 6.5 59 3.6
Rheumatoid arthritis 234 2.6 30 12.8 424 1.7 49 11.6
Seizures 1066 11.8 54 5.1 1797 7.1 83 4.6
Smoking-related disorder 950 10.5 49 5.2 1784 7.1 62 3.5
Stroke 1555 17.2 71 4.6 2385 9.4 100 4.2
Thyroid disease 1362 15.1 84 6.2 3439 13.6 136 4.0
Previous medication exposuresd
Antiandrogen 1043 11.5 65 6.2 1837 7.3 68 3.7
Antidepressants 2198 24.3 118 5.4 3846 15.2 177 4.6
Antiepileptic medications 1066 11.8 54 5.1 1797 7.1 83 4.6
Finasteride 538 6.0 28 5.2 880 3.5 29 3.3
Glucocorticoids 1257 13.9 98 7.8 1326 5.3 95 7.2
GnRH analog 223 2.5 32 14.3 259 1.0 34 13.1
H-2 receptor antagonists 2718 30.1 133 4.9 4812 19.1 194 4.0
Heparin 710 7.9 32 4.5 128 0.5 7 5.5
Loop diuretics 2431 26.9 142 5.8 3644 14.4 112 3.1
Opioids 4321 47.8 251 5.8 4734 18.8 195 4.1
Psychiatric medications 1302 14.4 75 5.8 2110 8.4 95 4.5
Spironolactone 448 5.0 20 4.5 875 3.5 25 2.9
Statins 5132 56.8 253 4.9 14,099 55.8 410 2.9
Testosterone 147 1.6 8 5.4 331 1.3 14 4.2
Thiazide diuretics 3124 34.6 161 5.2 7421 29.4 211 2.8
Key: BMI – body mass index; GnRH – Gonadotropin Releasing Hormone.
a Visit density is defined as the number of inpatient or outpatient encounters in the 1-year prior to the index date; it is a surrogate indicator of system familiarity with the patient
b % based on patients with non-missing race data (n=6091 for primary care patients and 9864 for specialty care patients)
c Each comparison is for the presence of each characteristic vs. absence.
d Clinical identification of osteoporosis or fracture risk is defined as (1) a diagnosis of osteoporosis, (2) a prescribed treatment for osteoporosis including calcitonin, parathyroid
hormone, or an osteoporosis bisphosphonate, or (3) an order for a bone mineral density test.
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pb .0001) were strong predictors of clinical identification of osteopo-
rosis. In addition, diagnoses of cancer, seizures, thyroid disease, and
exposure to antidepressants, glucocorticoids, H-2 receptor antago-
nists, and opioids were significantly associated with increased identi-
fication of osteoporosis in specialty care patients.
Discussion
We sought to identify patient and clinical characteristics that were
associated with identification and treatment of osteoporosis in a co-
hort of male US veterans to better understand information constructs
that might inform decision-making among clinicians. We did this
using time-varying covariates to better model the clinical pathway
and timing in which certain clinical or patient characteristics may
lead the provider to diagnose, test for, or treat osteoporosis. We dis-
covered that the strongest predictors of osteoporosis identification
in both primary care and specialty care patients included exposure
to GnRH analogs, fragility fractures, and diagnosis of rheumatoid ar-
thritis. We also found differences in the risk factors that were signifi-
cantly associated with identification of osteoporosis risk between
patients with at least one primary care visit in the VA compared to
those with only specialty care visits. For instance, deep vein thrombo-
sis, fall history, stroke, and exposure to loop diuretics were all signif-
icant predictors of the outcome in primary care patients but not
Table 2
Results of univariate and multivariable analyses for predictors of clinical identification of osteoporosis of fracture riska.
Characteristic Primary care visit (9037 patients; 102,541 observations) Specialty care visits only (25,245 patients; 278,175 observations)
Unadjusted hazards for outcomea Adjusted hazards for outcomea Unadjusted hazards for outcomea Adjusted hazards for outcomea
HR P value 95% CI HRb P value 95% CI HR P value 95% CI HRb P value 95% CI
Age
70–74 (ref) – – – – – – – – – – – – – – – –
75–79 vs. 70–74 1.167 0.233 0.906 1.504 – – – – 1.060 0.508 0.892 1.261 – – – –
≥80 vs. 70–74 1.338 0.019 1.050 1.705 – – – – 1.173 0.061 0.992 1.387 – – – –
BMI Normal/underweight vs.
overweight/obese
1.356 0.002 1.122 1.638 1.290 0.012 1.057 1.573 1.720 b.0001 1.489 1.988 1.625 b.0001 1.401 1.886
Visit densityc
b 10 (ref) – – – – – – – – – – – – – – – –
10–19 vs. b 10 0.835 0.464 0.515 1.353 – – – – 1.153 0.174 0.939 1.415 1.046 0.670 0.851 1.285
20–29 vs. b 10 1.147 0.524 0.752 1.750 – – – – 1.688 b.0001 1.385 2.057 1.236 0.043 1.007 1.519
30–39 vs. b 10 1.657 0.014 1.108 2.476 – – – – 2.324 b.0001 1.885 2.867 1.297 0.028 1.028 1.637
White vs. non-whited 0.994 0.973 0.684 1.443 – − – – 1.241 0.306 0.821 1.877 – – – –
Pre-existing conditionse
Alcohol abuse-related disorder 0.874 0.522 0.580 1.318 – – – – 1.318 0.146 0.908 1.912 – – – –
Blindness 1.090 0.460 0.868 1.368 – – – – 1.453 0.000 1.182 1.786 1.215 0.072 0.983 1.501
Cancer 1.964 b.0001 1.634 2.360 1.502 b.0001 1.235 1.827 1.868 b.0001 1.616 2.158 1.349 0.000 1.154 1.578
Deep vein thrombosis 1.832 0.000 1.325 2.535 1.452 0.026 1.045 2.017 1.599 0.017 1.086 2.353 – – – –
Depression 1.284 0.015 1.051 1.570 – – – – 1.592 b.0001 1.343 1.888 – – – –
Diabetes 1.198 0.061 0.991 1.447 – – – – 1.182 0.021 1.026 1.362 – – – –
Falls 2.461 b.0001 1.984 3.052 1.658 b.0001 1.310 2.098 2.026 b.0001 1.472 2.788 – – – –
Fragility fracture 3.610 b.0001 2.630 4.956 2.394 b.0001 1.711 3.351 4.804 b.0001 3.173 7.274 3.022 b.0001 1.977 4.620
Heart failure 1.184 0.098 0.970 1.446 – – – – 1.373 0.002 1.125 1.677 – – – –
Hypertension 1.065 0.675 0.794 1.429 – – – – 1.061 0.548 0.875 1.287 – – – –
Malnutrition disorder 1.941 b.0001 1.569 2.401 1.426 0.002 1.141 1.782 2.283 b.0001 1.794 2.905 1.254 0.084 0.970 1.621
Myocardial infarction 0.967 0.791 0.751 1.244 – – – – – – – – – – – –
Rheumatoid arthritis 3.015 b.0001 2.180 4.169 1.961 b.0001 1.406 2.736 4.260 b.0001 3.260 5.567 2.759 b.0001 2.090 3.642
Seizures 1.048 0.719 0.811 1.354 – – – – 1.642 b.0001 1.337 2.017 1.274 0.025 1.031 1.575
Smoking-related disorder 1.035 0.809 0.785 1.364 – – – – 1.249 0.062 0.989 1.578 – – – –
Stroke 0.892 0.332 0.709 1.123 0.786 0.041 0.623 0.990 1.337 0.003 1.102 1.623 – – – –
Thyroid disease 1.290 0.026 1.031 1.613 1.230 0.073 0.981 1.541 1.446 b.0001 1.216 1.720 1.415 b.0001 1.190 1.682
Previous medication exposurese
Antiandrogen 1.200 0.132 0.946 1.522 – – – – 1.501 b.0001 1.224 1.839
Antidepressants 1.217 0.047 1.003 1.478 – – – – 1.711 b.0001 1.462 2.003 1.303 0.002 1.107 1.534
Antiepileptic medications 1.048 0.719 0.811 1.354 – – – – 1.642 b.0001 1.337 2.017 – – – –
Finasteride 0.934 0.693 0.667 1.308 – – – – 1.380 0.023 1.046 1.822 – – – –
Glucocorticoids 2.454 b.0001 2.025 2.974 1.913 b.0001 1.565 2.339 3.211 b.0001 2.685 3.840 2.178 b.0001 1.802 2.632
GnRH analog 4.102 b.0001 3.054 5.510 2.801 b.0001 2.061 3.808 5.931 b.0001 4.457 7.892 4.076 b.0001 3.020 5.502
H-2 receptor antagonists 1.008 0.937 0.834 1.217 0.828 0.057 0.682 1.006 1.537 b.0001 1.320 1.790 1.286 0.002 1.100 1.503
Heparin 1.267 0.070 0.981 1.637 – – – – 3.074 b.0001 1.955 4.832 – – – –
Loop diuretics 1.506 b.0001 1.250 1.814 1.220 0.043 1.007 1.479 1.202 0.038 1.010 1.430 – – – –
Opioids 1.754 b.0001 1.438 2.139 1.288 0.018 1.044 1.589 1.854 b.0001 1.603 2.145 1.254 0.006 1.068 1.472
Psychiatric medications 1.272 0.031 1.022 1.582 – – – – 1.516 b.0001 1.245 1.848 – – – –
Spironolactone 1.000 1.000 0.696 1.437 – – – – 1.042 0.811 0.744 1.458 – – – –
Statins 0.940 0.513 0.779 1.133 – – – – 0.917 0.238 0.795 1.059 – – – –
Testosterone b10 events b10 events 2.030 0.001 1.359 3.030 – – – –
Thiazide diuretics 0.972 0.764 0.806 1.171 – – – – 0.903 0.188 0.777 1.051 – – – –
Key: HR – hazards ratio; CI – confidence interval; BMD – bone mineral density; BMI – body mass index; GnRH – Gonadotropin Releasing Hormone.
a Clinical identification of osteoporosis or fracture risk is defined as (1) a diagnosis of osteoporosis, (2) a prescribed treatment for osteoporosis including calcitonin, parathyroid
hormone, or an osteoporosis bisphosphonate, or (3) an order for a bone mineral density test.
b Adjusted for all other variables with estimates shown
c Visit density is defined as the number of inpatient or outpatient encounters in the 1-year prior to the index date; it is a surrogate indicator of system familiarity with the patient
d Based on patients with non-missing race data (n=6091 for primary care patients and 9864 for specialty care patients)
e Each comparison is for the presence of each characteristic vs. absence.
986 R.E. Nelson et al. / Bone 50 (2012) 983–988
specialty care patients, whereas the opposite was true for seizures
and exposure to antidepressants. Interestingly, some characteristics
were strong clinical predictors of osteoporosis did not appear to be
associated with the outcome of clinical identification in either pri-
mary care or specialty care patients, such as smoking- and alcohol-
related disorders. This suggests that clinicians are paying attention
to some potential cues, but may be missing others.
Our findings do provide support for the conclusion that clinicians
consider some risk factor constructs and important cues for osteoporo-
sis risk. For example, we found that BMI was negatively associatedwith
the outcome, consistent with previous literature [17], on which case-
finding strategies recommended in current best practice guidelines
are based [18]. Additionally, both prior fractures and falls, which are
among the strongest predictors of future fractures [19–25], were strong
predictors in our study. Similarly, exposure to oral glucocorticoids,
which was significantly predictive of the outcome in both models, is
also widely known to be associated with poor bone health and fracture
[26–31].
Many of the significant risk factors identified in primary care pa-
tients were also present in the specialty care model. However, several
inconsistencies in risk factors identified for primary care patients com-
pared to specialty care patients highlight the differences in these two
types of care. Risk factors significantly associated with clinical identifi-
cation of osteoporosis for specialty care patients but not primary care
patients were conditions that are familiar to specialists. For example, a
psychiatrist would likely be aware of the association between selective
serotonin reuptake inhibitor use and increased risk of fracture [32].
Similarly, the association between seizures and osteoporosis would be
recognized by neurologists.
While many diagnoses and medications were associated with clini-
cal identification of osteoporosis in both primary and specialty care pa-
tients, risk factors that are more behavioral in nature such as alcohol
abuse and smoking status were not. Previous studies have found that
clinicians spend less time discussing alcohol use with patients than
other health-related behaviors [33]. Clinicians, therefore, may be miss-
ing opportunities to make the connections between alcohol abuse and
its consequences. The poorly captured nature of smoking status in
ICD-9 codes may explain the lack of significance in our models [34].
In terms of quality performance measures, the VHA generally ex-
ceeds those seen outside the VHA setting in numerous disease states, in-
cluding human immunodeficiency virus [35], colorectal cancer [36],
hyperlipidemia [37], and hypertension [38]. In fact, a recent study sug-
gests that because of efforts to improve care in these other diseases that
are much more common in males, the VHA have lagged behind other
health systems in the diagnosis and treatment of osteoporosis [39].
We echo these authors' sentiments that this represents an opportunity
for the VHA to improve the management of fractures and fracture risk
among veterans.
Limitations
The major limitation in this analysis was that each patient's true
underlying osteoporosis risk was not known. Our cohort consisted
of all veterans who met inclusion criteria, including those with and
without high fracture risk. Because our goal was to test which con-
structs were associated with identifying osteoporosis, it would have
been ideal to have a cohort in which underlying osteoporosis risk
was known to researchers (but unknown to clinicians at baseline)
and to restrict the analysis to those patients who had high risk. How-
ever, we know of no such data for veterans. Nonetheless, because all
our potential predictors have a known or theoretical association
with fracture or bone quality, our results are robust to that issue. Pa-
tients with the exposures and characteristics of interest are, by defini-
tion, at a higher risk for fracture than those without. Other minor
limitations include that we may have incomplete capture of out-
comes, particularly those based on procedure and diagnosis codes.
While the low cost of prescriptions in the VHA provides an incentive
for eligible veterans to obtain all of their prescriptions in the system,
it is known that many veterans utilize outside systems for non-
pharmaceutical care. If patients who obtain care from both VHA and
non-VHA facilities are systematically different than those who use
VHA exclusively, as several recent studies suggest [40–42], then this
could bias the results in a variety of ways. We mitigated this limita-
tion by restricting our analysis to veterans who had demonstrated a
pattern of utilizing the VHA system for inpatient or outpatient care
as well as identifying patients who had received at least one primary
care visit prior to index. Additionally, patients with missing BMI
values were excluded from our analysis. Patients with missing BMI
differed significantly from patients with non-missing BMI on age,
race, and number of visits. This suggests that BMI values were not
missing at random in our study and that excluding them from our
analysis may have introduced selection bias. A final limitation is
that patients in this study were US veterans receiving care within
one specific region of the VHA system (VISN 19) and may not be gen-
eralizable to veterans in other regions of the US.
Future work
The results of this study suggest that treatment and testing deci-
sions can be better aligned with risk factors for osteoporosis fractures.
Clinical reminders and other interventions designed to assist clini-
cians in identifying osteoporosis risk could improve osteoporosis pre-
vention in the VHA.
Conclusion
In this study, we found that many patient characteristics identified
in clinical and administrative datasets were associated with clinical
identification of osteoporosis risk in a cohort of male US veterans
age 70 and older. However, several other known risk factors were
not associated with the outcome. Future work should focus on help-
ing clinicians identify patients with high risk for fracture.
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